Medical cannabis products require precise cannabinoid quantification for therapeutic efficacy, regulatory compliance, and patient safety - THC and CBD ratios determine pharmacological effects while regulatory limits prevent psychoactive exposure. Comprehensive cannabinoid profiling following Swissmedic requirements quantifies THC, CBD, and related compounds in medical cannabis products through GC-MS analysis distinguishing between psychoactive and therapeutic cannabinoids. This analysis ensures products meet regulatory limits with THC quantification confirming levels remain below psychoactive thresholds for CBD products, CBD quantification validating therapeutic content matching labeled claims, and related cannabinoid profiling providing complete chemical characterization. Critical for medical cannabis quality control ensuring batch-to-batch consistency in cannabinoid content, validating THC levels remain below legal limits in CBD products preventing psychoactive effects, and supporting product registration for cannabis-based medicines requiring comprehensive cannabinoid characterization. The GC-MS methodology provides definitive cannabinoid identification through mass spectral confirmation, quantifies major cannabinoids including THC, CBD, CBN, and CBG providing complete profiles, and detects degradation products indicating improper storage or aging. For pharmaceutical cannabis applications, cannabinoid profiling validates extraction processes achieve target cannabinoid ratios, demonstrates stability throughout shelf life maintaining therapeutic potency, and supports dosing claims ensuring patients receive consistent cannabinoid exposure. Swiss medical cannabis regulations require documented cannabinoid testing for product authorization with ongoing batch release testing maintaining compliance, while international markets increasingly demand similar data for medical cannabis product approval.